Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Patent prosecution for drug discovery company
Represent an emerging drug discovery company with small and large molecule therapeutics with respect to patent prosecution and related counseling. more
Distribution alliance in Australia and Dubai for leading providers of lighting equipment
Representing one of the leading providers of lighting fixtures regarding a strategic alliance with partners from Australia and Dubai for the more
Medical malpractice
Represented a widower after his wife died due to healthcare negligence.  The case resulted in one of the largest medical malpractice settlements ever more
Sale/leaseback by BB&T Corporation
Represented Branch Banking & Trust in multiple proposed sale/leaseback transactions involving approximately 1,000 bank properties. more